Generic pantoprazole hits Nycomed's turnover
This article was originally published in Scrip
An "at-risk" generic launch of pantoprazole in December affected Nycomed's first-half net turnover, which fell by 3% to €1.71 billion. The loss of Protonix sales to two generic versions by Teva and Sun Pharmaceutical Industries was felt most greatly in North America, Spain and the UK. Nycomed's gross profit was almost flat at €1.3 billion during this reporting period.